Tenofovir: full impurity supply

   Tenofovir is an antiviral drug used to treat HIV and chronic hepatitis B (CHB). Its mechanism of action is mainly by inhibiting the reverse transcriptase of the virus, thus stopping viral replication. Specifically, tenofovir is an open-cyclic phosphonate nucleotide reverse transcriptase inhibitor, which is converted intracellularly to the active metabolite tenofovir diphosphate (TFV-DP), which competitively inhibits the viral reverse transcriptase enzyme and hinders the synthesis of viral DNA.

  Current research on tenofovir impurities focuses on impurities that may occur during the synthesis process of the drug, such as raw materials that are not hydrolysed during synthesis, impurities that do not undergo condensation reactions, and impurities formed by partial hydrolysis.

  In terms of the human limits of impurities, the International Pharmacopoeia (WHO 11th edition) for tenofovir stipulates the following limits: the area of any peak due to tenofovir monoester (impurity A, relative retention time 0.5 min) is not more than 7 times the main peak area (3.5%); the area of any other impurity peak is not more than the main peak area (0.5%), and the area of no more than two such peaks is greater than 0.4 times (0.2%) the area of the main peak.

  With the continuous updating and development of modern medicine, the demand for new drugs is also expanding, providing a favourable premise for the development and research of Tenofovir.SZEB supplies a full set of Tenofovir impurity control/standard products, more excellent quality and service, help solve the problem of drug impurities in drug research. For more information about impurities, please go to the official website—— www.bio-tech.com to view, if necessary, please  contact us 。